Cosmo Pharmaceuticals N.V. reiterated earnings guidance for the Year 2023 . For the year, company expects total revenue between EUR 110 million and EUR 120 million, operating profit between EUR 25 million and EUR 35 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.6 CHF | -0.69% | +0.28% | +40.67% |
Apr. 25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.67% | 1.26B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023